CMMB - Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update

PR Newswire

This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023

TEL AVIV, Israel , April 12, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023 , at 8:00 am Eastern Time .

This webcast and call replaces and supplements a previously announced Corporate Update event that had been scheduled for April 17, 2023 .

During the event, Chemomab's management team will review first quarter 2023 performance, discuss recent and upcoming developments and conduct a live question-and-answer session.

A replay of the webcast and call will be available on Chemomab's website for 90 days at www.chemomab.com .

Live Webcast and Conference Call at 8:00 am Eastern Time , Thursday, May 11, 2023

Click this Webcast link to access the live webcast or replay.

The live webcast and replay can also be accessed at the News & Events section of the Investors page on the Chemomab website at investors.chemomab.com/events .

Conference Call Access via Telephone

• US Investors:                 +1 (877) 407-9208
• International Investors:   +1 (201) 493-6784
• Conference ID code:      13735393

Please call 5-10 minutes before the scheduled start time, enter the conference passcode and ask the operator for the Chemomab conference call.

Or click on Call me ^TM starting 15 minutes before the scheduled start time for instant telephone access without having to wait for an operator.

About Chemomab Therapeutics
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in hospitalized patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin enrolling patients around midyear 2023. For more information on Chemomab, visit chemomab.com .

Contacts:

SOURCE Chemomab Therapeutics, Ltd.